SMH’s Kolschowsky Research and Education Institute is enrolling patients in a research study evaluating LINFU (Low-Intensity Non-Focused Ultrasound), an emerging screening technology designed to help doctors identify precancerous changes in people at high risk for pancreatic cancer, but who have no signs or symptoms of the disease. Kenneth Meredith, MD, chief of gastrointestinal oncology at SMH’s Brian D. Jellison Cancer Institute and principal investigator of the local study, says the screening represents an important step forward in pancreatic cancer research. Learn more about this at smh.com/news and check out other interviews with SMH experts at smh.com/podcast, and subscribe on your favorite streaming app.
